Navigation Links
Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY
Date:10/19/2009

BERWYN, Pa., Oct. 19 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced that it has completed a private placement of 3,937,500 shares of its common stock with a private investor for an aggregate purchase price of $1,575,000, or $.40 per share.

Prior to the transaction, the Company has entered into Warrant Exchange Agreements with two investors (the "Investors") pursuant to which the Company issued to the Investors an aggregate of 1,864,000 shares of Common Stock (collectively, the "Exchange Shares") and warrants to purchase an aggregate of 874,126 shares of Common Stock, exercisable for a period of five years, at an exercise price of $.40 per share (collectively, the "Exchange Warrants"). The Exchange Shares and Exchange Warrants were issued in exchange for warrants dated as of May 9, 2007 held by the Investors to purchase an aggregate of 874,126 shares of Common Stock of the Company (collectively, the "Original Warrants").

The Company also announced that it has terminated previously announced negotiations for the sale of the Company's wholly-owned subsidiary Encorium OY to a clinical research organization based in the United States and will not pursue a sale of the Company or Encorium OY at this time. Given the Company's recent successes with respect to its strategy to grow into the world's leading vaccine franchise, including the recently announced $8.7 million of new business contract wins and the selection by a major pharmaceutical company for participation in a swine flu vaccine program, together with the investment announced today, the Company believes it is well
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Encorium Group, Inc. Announces New Business Awards of $8.7 Million, Including Swine Flu (Influenza A H1N1 virus) Vaccine Trial Win;
2. Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing
3. Encorium Reports Second Quarter 2009 Financial Results
4. Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes
5. Encorium Group Updates Expected Timeframe with Respect to the Sale of its U.S. Business
6. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
7. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
8. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
9. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
10. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
11. Encorium Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Scientists, including University of Oregon chemist Geraldine Richmond, ... of self-assembling, synthetic proteins called peptoid nanosheets that ... accomplishment -- detailed this week in a paper ... Proceedings of the National Academy of Sciences ... of the two-dimensional peptoid nanosheets that can be ...
(Date:9/2/2014)... , Sept. 2, 2014  Technology Applications International ... that its wholly-owned subsidiary Renuell Int,l, Inc. has signed ... and Space Administration ("NASA") at the Johnson Space Center ... See photos: tapplic.com/houstonphotos/ ... are very pleased to announce our latest, exclusive agreement ...
(Date:9/2/2014)... , Sept. 2, 2014  Xencor, Inc. ... company developing engineered monoclonal antibodies for the treatment ... cancer, today announced the appointment of Debra ... and the appointment of Lloyd Rowland , ... counsel. "Debra,s expertise in biologics ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 PMG ... its 11th clinical research site: PMG Research of Rocky ... and operation of the clinical research department at ... PMG’s presence in eastern North Carolina. This new site ... the patients in Rocky Mount and the surrounding communities, ...
Breaking Biology Technology:UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3
... /PRNewswire/ -- The Nano Science and Technology Institute ... will take place May 3-7, 2009 at the George R. ... 12th year, the largest and most prominent Nanotechnology event is ... Micro and Bio technology executives, who will gather to promote ...
... CLINTON, N.J., Jan. 8 Ikaria Holdings, Inc. today ... present at the 27th Annual JPMorgan Healthcare Conference on ... The conference will be held January 12-15 at The ... Holdings, Inc. , Ikaria Holdings, Inc. is a ...
... /PRNewswire/ - Aegera Therapeutics Inc. announced today the ... Phase 2 study of AEG35156, their targeted antisense ... , The study, entitled "A Phase 2, Multicenter, ... Apoptosis (XIAP) Antisense AEG35156 Given In Combination With ...
Cached Biology Technology:NSTI Announces the 12th Annual Nanotech Conference & Expo 2009 May 3-7, at the George R. Brown Convention Center in Houston, Texas 2NSTI Announces the 12th Annual Nanotech Conference & Expo 2009 May 3-7, at the George R. Brown Convention Center in Houston, Texas 3NSTI Announces the 12th Annual Nanotech Conference & Expo 2009 May 3-7, at the George R. Brown Convention Center in Houston, Texas 4Ikaria(R) to Present at 27th Annual JPMorgan Healthcare Conference 2Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer 2
(Date:9/1/2014)... after birth, every child in the U.S. undergoes a ... conditions, including sickle cell disease. Thousands of children born ... many suffer and die from the disease each year. ... to at least some of those deaths. , ... in the lab of George Whitesides, the Woodford L. ...
(Date:9/1/2014)... basic building block of DNAcould initiate fragile X syndrome, the most ... The Journal of Cell Biology . , ... on the X chromosome called fragile X mental retardation 1 ... men carry a so-called premutation, in which a series of DNA ... slightly longer than normal. These repeats are prone to even further ...
(Date:9/1/2014)... to a life without light. They emit echolocation sounds and ... to obstacles or prey. In their brains, they have a ... by researchers at Technische Universitt Mnchen (TUM) has shown for ... factors. , Closer objects appear larger ... object, the number of activated neurons in its brain increases. ...
Breaking Biology News(10 mins):Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3A nucleotide change could initiate fragile X syndrome 2Zooming in for a safe flight 2
... June 1, 2010 -- The National Oceanic and Atmospheric ... of Miami (UM) to continue to lead its partnership ... (CIMAS). NOAA and UM scientists have worked ... of climate, hurricanes, and marine ecosystems along the southeastern ...
... Since the 1990s, a green fluorescent protein known simply as ... Northwest jellyfish, GFP allows scientists to visualize proteins inside of ... Two years ago, biologists who discovered and developed the protein ... work. However, using GFP as a fluorescent probe has ...
... viable due to aberrant chromosome distribution if they had ... German Cancer Research Center have investigated which genes are ... revealed that cancer cells rely on the tension ... Thus, proteins which maintain this tension are promising targets ...
Cached Biology News:NOAA selects University of Miami to lead major southeastern US cooperative institute 2NOAA selects University of Miami to lead major southeastern US cooperative institute 3MIT chemists design new way to fluorescently label proteins 2No relaxing for cancer cells 2
The Programmable MP-5000P-F Power Supply can be applied for any Microfluidic application....
...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
... Major Science Smart Minis 150V power supply ... mini power supplies designed to meet most ... to use unit. The Minis 150V power ... The Minis Power Supply is designed for ...
Biology Products: